Zyvox

Linezolid

Gm +ve bacteria; vancomycin-resistant Enterococcus faecium infections including cases w/ concurrent bacteremia; nosocomial pneumonia caused by Staph aureus (methicillin-susceptible & -resistant strains) or Strep pneumoniae (including multi-drug resistant strains [MDRSP]); complicated skin & skin structure infections including diabetic foot infections w/o concomitant osteomyelitis caused by Staph aureus (methicillin-susceptible & -resistant strains), Strep pyogenes or Strep agalactiae; uncomplicated skin & skin structure infections caused by Staph aureus (methicillin-susceptible only) or Strep pyogenes; community-acquired pneumonia caused by Strep pneumoniae (including MDRSP) including cases w/ concurrent bacteremia or Staph aureus (methicillin-susceptible strains only).

Adult & adolescent ≥12 yr Complicated skin & skin structure infections, nosocomial & community-acquired pneumonia including concurrent bacteremia 600 mg IV or PO every 12 hr for 10-14 days. Vancomycin-resistant Enterococcus faecium infections including concurrent bacteremia 600 mg IV or PO every 12 hr for 14-28 days. Uncomplicated skin & skin structure infections 400 mg PO every 12 hr for 10-14 days in adults & 600 mg PO every 12 hr for 10-14 days in adolescents ≥12 yr. Infection due to MRSA 600 mg every 12 hr in adult. Ped patients (birth through 11 yr) Complicated skin & skin structure infections, nosocomial & community-acquired pneumonia including concurrent bacteremia 10 mg/kg IV or PO every 8 hr for 10-14 days. Vancomycin-resistant Enterococcus faecium infections including concurrent bacteremia 10 mg/kg IV or PO every 8 hr for 14-28 days. Uncomplicated skin & skin structure infections 10 mg/kg PO every 12 hr for 10-14 days in childn 5-11 yr & 10 mg/kg PO every 8 hr for 10-14 days in childn <5 yr. Pre-term neonate <7 days (gestational age <34 wk) Initially 10 mg/kg every 12 hr. May be given 10 mg/kg every 8 hr by 7 days of life.

May be taken with or without food.

Hypersensitivity. Patients w/ uncontrolled HTN, pheochromocytoma, thyrotoxicosis; carcinoid syndrome. Concomitant use w/ MAOIs A or B (eg, phenelzine, isocarboxazid); directly & indirectly acting sympathomimetics (eg, pseudoephedrine, phenylpropanolamine), vasopressive agents (eg, epinephrine, norepinephrine), dopaminergic agents (eg, dopamine, dobutamine); serotonin re-uptake inhibitors, TCAs, serotonin 5-HT₁ receptor agonists (triptans), meperidine, buspirone.

Consider discontinuation if myelosuppression develops or worsens. Not for use against gm -ve pathogens; in patients w/ catheter-related bloodstream infections; viral infections eg, common cold. Clostridium difficile-associated diarrhea; pseudomembranous colitis in patients w/ diarrhea. Superinfection. Lactic acidosis. Hyponatremia & SIADH. Peripheral & optic neuropathy in patients treated >28 days. Convulsions; history or risk factors for seizures; history of HTN. Long-term use (>28 days). Patients who develop recurrent nausea or vomiting, unexplained acidosis or low bicarbonate level while on treatment. Patients w/ uncontrolled HTN, pheochromocytoma, carcinoid syndrome or untreated hyperthyroidism; at high risk for life-threatening systemic infections. Monitor CBC wkly especially in patients treated for >2 wk w/ pre-existing myelosuppression, severe renal insufficiency & moderate to severe hepatic impairment & receiving concomitant drugs that produce bone marrow suppression, or w/ chronic infection who have received previous or concomitant antibiotic therapy. Consider fluid & electrolyte management, protein supplementation & treatment w/ antibacterial against Clostridium difficile. Closely observe patients for signs & symptoms of serotonin syndrome eg, cognitive dysfunction, hyperpyrexia, hyperreflexia & incoordination. Regularly monitor serum Na levels in elderly, patients taking diuretics & at risk of hyponatremia. Prompt ophth evaluation if visual impairment symptoms appear eg, changes in visual acuity & color vision, blurred vision or visual field defect. Monitor visual function in all patients treated for extended periods (≥3 mth) & patients reporting new visual symptoms regardless of length of therapy. Avoid large quantities of food or beverages w/ high tyramine content. Concomitant use w/ serotonergic agents, including antidepressants eg, SSRIs & opioids; rifampin; pseudoephedrine HCl- or phenylpropanolamine HCl-containing cold remedies & decongestants; serotonin re-uptake inhibitors or other antidepressants. Thrombocytopenia in patients w/ severe renal insufficiency, whether or not on dialysis, & in patients w/ moderate to severe hepatic impairment. Pregnancy & lactation.

Moniliasis; pancytopenia, leucopenia, thrombocytopenia, anemia, sideroblastic anemia; anaphylaxis; lactic acidosis; convulsions, peripheral neuropathy, headache, taste alteration; optic neuropathy; vomiting, diarrhea, nausea, abdominal pain, cramps & distension, tongue discoloration, superficial tooth discoloration; bullous skin disorders including severe cutaneous adverse reactions (eg, TEN & SJS), angioedema, hypersensitivity vasculitis, rash; abnormal hematology tests & LFTs.

Reversible enhancement of pressor response to indirect-acting sympathomimetics, vasopressor or dopaminergics. Serotonin syndrome w/ serotonergic agents including antidepressants eg, SSRIs.

Other Antibiotics

J01XX08 - linezolid ; Belongs to the class of other antibacterials. Used in the systemic treatment of infections.

FC tab: D; Infusion: S